Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H38N2O6 |
Molecular Weight | 534.6432 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)CC2(CCCC2)C(=O)N[C@H]3CCC4=CC=CC=C4N(CC(O)=O)C3=O
InChI
InChIKey=XMQODGUTLZXUGZ-RPBOFIJWSA-N
InChI=1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12735234Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/25131455
http://adisinsight.springer.com/drugs/800010577
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12735234
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/25131455
http://adisinsight.springer.com/drugs/800010577
The new chemical entity KC12615 is a potent f neutral endopeptidase inhibitor with additional endothelin-converting enzyme (ECE)–inhibitory activity.2 KC12615 is the hydrolyzed form of the oral prodrug SLV306 (daglutril). In plasma, the compound increases natriuretic peptide levels and prevents the formation of endothelin-1 by inhibiting the degradation of its precursor, big endothelin. It is investigated for use/treatment in congestive heart failure and hypertension.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1944 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12735234 |
4.2 nM [IC50] | ||
Target ID: CHEMBL4791 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12735234 |
1.5 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
yes [IC50 7.5637 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00160212
150, 300, 600 mg Once Daily or 150-300 mg Twice Daily
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C783
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
182821-27-8
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
3038505
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
DB05796
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107738
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
8351
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
C73039
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
100000175036
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
KKV299446X
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY | |||
|
DTXSID60171341
Created by
admin on Fri Dec 15 16:34:19 GMT 2023 , Edited by admin on Fri Dec 15 16:34:19 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PRODRUG)